August 21, 2014 — Efforts over the past decade to improve the quality of care for cardiovascular disease patients and increase the use of evidence-based treatments have led to a significant drop in the rate of hospitalizations and deaths, according to a new study released in the journal Circulation. The results emphasize the value of recent efforts by the cardiovascular community to support the delivery of timely, high-quality care to patients.

August 21, 2014 — Corindus Vascular Robotics announced the results of a retrospective study comparing use of radiation and contrast for patients enrolled in its CorPath PRECISE (Percutaneous Robotic-Enhanced Coronary Intervention) study to a matched traditional manual PCI (percutaneous coronary intervention) patient, published in the July 2014 issue of the Journal of Invasive Cardiology.

Regenerative medicine experts at the Cedars-Sinai Heart Institute have opened a new clinic to evaluate heart and vascular disease patients for participation in stem cell medical studies.

Cardiva Medical Inc. said it closed the first two tranches of a $16.5 million Series 3 private equity financing and a $12.5 million senior secured facility with GE Capital. The company will use the proceeds of the Series 3 private equity financing and debt facility to expand commercial efforts for its Vascade vascular closure system in the United States.

NorthStar Medical Radioisotopes LLC signed a non-exclusive letter of intent with GE Healthcare, a division of General Electric Co., marking further progress toward establishing the first existing commercially viable domestic source of the radioisotope 99molybdenum (99Mo).

 

GE Healthcare introduces the Vscan with Dual Probe with the first of its kind 2-in-1 probe to give healthcare providers more uses for pocket ultrasound.

U.S. Department of Justice Close Investigation PLATO Clinical Trial Ticagrelor

AstraZeneca announced it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial that tested the safety and effectiveness of the blood thinner ticagrelor (Brilinta). 

Boston Scientific Corp. and Asahi Intecc have formalized plans to develop a new, differentiated fractional flow reserve (FFR) wire. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now